FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHA Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor [NCT06065540]RESEARCHSemaglutide in Alcohol Use Disorder [NCT07949474]RESEARCHEffects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease [NCT06409130]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]NEWS‘Selling and marketing snake oil’: The debate over compounded GLP-1sRESEARCHSemaglutide Effects on Sperm Concentration in Overweight Infertile Men [NCT07946796]RESEARCHTirzepatide for the REduction of AceTazolamide in Idiopathic Intracranial Hypertension [NCT07946315]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHA Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor [NCT06065540]RESEARCHSemaglutide in Alcohol Use Disorder [NCT07949474]RESEARCHEffects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease [NCT06409130]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]NEWS‘Selling and marketing snake oil’: The debate over compounded GLP-1sRESEARCHSemaglutide Effects on Sperm Concentration in Overweight Infertile Men [NCT07946796]RESEARCHTirzepatide for the REduction of AceTazolamide in Idiopathic Intracranial Hypertension [NCT07946315]

Para fines de investigación únicamente. Aviso completo →

Investigación/Highlighting the efficacy and importance of continued GLP-1 receptor agonist therapy, specifically semaglutide, in maintaining weight loss for patients with obesity or overweight.
Volver a Biblioteca de Investigación
semaglutideGLP-1 receptor agonist

Highlighting the efficacy and importance of continued GLP-1 receptor agonist therapy, specifically semaglutide, in maintaining weight loss for patients with obesity or overweight.

May 17, 2026
Share

Fuente del Paper

Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.

Rubino Domenica et al.JAMA2021
Investigación Emergente

Basado en investigación emergente. Estos hallazgos son prometedores pero requieren validación adicional.

Sobre este análisis

Este artículo descompone los hallazgos del paper fuente anterior en lenguaje accesible para la comunidad de investigación de péptidos. Nuestro objetivo es destacar lo más importante — las implicaciones prácticas, la fuerza de la evidencia y lo que significa para la investigación en curso.

Maintaining Weight Loss with Semaglutide: A New Hope for Obesity Management

Published: May 17, 2026 | Source: JAMA (2021) | Category: semaglutide, GLP-1 receptor agonist

Overview

A recent study published in the Journal of the American Medical Association (JAMA) highlights the efficacy of continued weekly subcutaneous semaglutide treatment for maintaining weight loss in adults with overweight or obesity. This research underscores the importance of sustained therapy using glucagon-like peptide 1 (GLP-1) receptor agonists like semaglutide to achieve long-term health benefits.

Study Background

Before this study, it was unclear whether continuing GLP-1 receptor agonist treatment after initial weight loss would be necessary for maintaining those results. Previous research had shown that these medications are effective in inducing significant weight loss, but questions remained about the optimal duration of therapy and whether patients could maintain their weight without continued medication.

What the Research Found

The STEP 4 randomized clinical trial involved 803 participants who initially received semaglutide for a 20-week period. After reaching a maintenance dose, these individuals were randomly assigned to either continue with semaglutide or switch to placebo for an additional 48 weeks. The primary outcome was the percentage change in body weight from week 20 to week 68.

The results showed that participants who continued taking semaglutide maintained their weight loss, experiencing a further reduction of -7.9% on average compared to those who switched to placebo, whose weight increased by +6.9%. Additionally, the study observed significant improvements in waist circumference and systolic blood pressure among those continuing with semaglutide.

What This Means for Peptide Users

For individuals using GLP-1 receptor agonists like semaglutide for weight management, this research suggests that discontinuing treatment may lead to rapid weight regain. Therefore, patients should consider the long-term benefits of sustained therapy and discuss continuation plans with their healthcare providers to ensure continued health improvements.

Limitations and Caveats

While the study provides valuable insights into the role of semaglutide in maintaining weight loss, it has several limitations. The relatively short follow-up period of 68 weeks may not be sufficient to assess long-term efficacy and safety. Additionally, participants with diabetes were excluded from this trial, which limits its applicability to a broader population.

How This Compares to Previous Research

Previous studies have also highlighted the effectiveness of GLP-1 receptor agonists in inducing weight loss but often did not address maintenance strategies beyond initial treatment phases. The STEP 4 study is unique in directly comparing continued therapy with discontinuation, providing clearer guidance on long-term management strategies.

Our Analysis

PeptideVault views this research as a significant step forward in understanding the role of GLP-1 receptor agonists like semaglutide for weight loss maintenance. However, it is crucial to acknowledge that further studies are needed to confirm these findings over longer periods and across diverse patient populations, including those with diabetes.

Key Takeaways

  • Sustained Therapy: Continued use of semaglutide can help maintain significant weight loss achieved during initial treatment phases.
  • Health Benefits: Beyond weight management, the study indicates additional health benefits such as improved waist circumference and blood pressure control.
  • Further Research Needed: Longer-term studies are essential to fully understand the long-term efficacy and safety of GLP-1 receptor agonists.

Original Source

Citation: Rubino Domenica, Abrahamsson Niclas, Davies Melanie et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.. JAMA. DOI: 10.1001/jama.2021.3224

Access:

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

Nota del Editor

Este análisis fue preparado por el equipo de investigación de Peptide Contacts. Se anima a los lectores a revisar la fuente completa del paper para metodología y datos completos. La publicación original está disponible en PubMed.

Investigación Relacionada

Comments

Sign in to join the discussion

Este análisis se genera a partir de investigación revisada por pares para fines educativos solo. No constituye consejo médico. Consulte siempre a un proveedor de atención médica calificado antes de usar cualquier terapia basada en péptidos.